Itraconazole Focus Pharmaceuticals Ltd (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By preventing ergosterol formation, the drug destabilises the fungal cell membrane, inhibiting growth and eventually causing cell death. Its selective action targets fungi while sparing human cholesterol pathways.

The specific dose of itraconazole is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals set the regimen and duration according to current clinical guidelines.

Safety data for itraconazole during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To request itraconazole, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with fluconazole, another azole antifungal, itraconazole has a broader spectrum against dermatophytes and certain systemic fungi but may have more drug‑interaction potential due to stronger CYP3A4 inhibition. Choice between them depends on the pathogen, infection site, patient comorbidities and interaction profile.

Itraconazole should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Itraconazole is taken orally, usually with food to improve absorption. The tablet or capsule should be swallowed whole with a full glass of water. Patients should follow the prescribing clinician’s instructions regarding timing, meal composition and any required therapeutic drug monitoring.

Serious risks include hepatotoxicity (liver injury), severe skin reactions such as Stevens‑Johnson syndrome, cardiac failure or arrhythmias, visual disturbances, and rare cases of anaphylaxis. Patients should report any unexplained jaundice, rash, shortness of breath, or vision changes to their healthcare provider promptly.

Itraconazole is contraindicated in individuals with known hypersensitivity to the drug or any azole antifungal. Patients with severe liver impairment, uncontrolled heart failure, or those taking contraindicated medications (e.g., strong CYP3A4 inducers) should avoid its use unless a specialist determines that benefits outweigh risks.